Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCT05857644 | Registry Identifier | ClinicalTrials.gov |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn how the study medicine (PF-07923568) is processed in participants with liver function loss compared to healthy participants. The different levels of liver function loss can be mild, moderate or severe.
This study is seeking participants who:
All participants will receive a one-time dose of 4 capsules of PF-07923568 which will be taken by mouth. All participants will remain at the study clinic for 6 days for safety review and laboratory collections. This is to see how the study medicine is being broken down by the liver over time.
All participants selected in the study will be required to go through a screening period up to 28 days. A screening period is the time during which a few participants are examined to see whether they are fit for the study. During this period, the participant's medical history and past and current medications will be reviewed. A series of tests will also be performed to see if they are good to be selected for the study. If the participant meets all required criteria and are interested in continuing, the participant will be brought into the study clinic to stay overnight for 6 days. On day 6, the participant will be discharged. About 28 to 35 days after discharge, the participant will be contacted for a follow up visit either in person or by telephone. This is to check up on how the participant is doing and to conclude the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy subjects | Experimental | One time dose of 4 capsules taken orally. |
|
| Mild Hepatic impaired subjects | Experimental | One time dose of 4 capsules taken orally. |
|
| Moderate hepatic impaired subjects | Experimental | One time dose of 4 capsules taken orally |
|
| Severe Hepatic Impaired Subjects | Experimental | One time dose of 4 capsules taken orally. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-07923568 | Drug | One time dose of 4 capsules taken orally. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Maximum Concentration (Cmax) of Sisunatovir Following Administration of a Single Oral Dose | Cmax was the highest concentration observed directly from data | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
| Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Sisunatovir Following Administration of a Single Oral Dose | AUClast was determined using linear/Log trapezoidal method | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
| Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Sisunatovir Following Administration of a Single Oral Dose | AUClast + (Clast*/kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminalphase rate constant. | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-related TEAEs, and Discontinuations From Study Due to TEAEs | Adverse event (AE) was any untoward medical occurrence in the participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Serious AE was any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or was considered to be an important medical event. Any events occurring following start of treatment or increasing in severity were counted as treatment-emergent. AEs included both serious and non-serious AEs. |
Not provided
Inclusion Criteria: for healthy volunteers:
BMI of 17.5 to 38.0 kg/m2, inclusive, and a total body weight >50 kg (110 lb).
Capable of giving signed informed consent.
At screening, no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, including BP and pulse rate measurement, standard 12-lead ECG and clinical laboratory tests.
body weight within +/-15 kg of the average of pooled hepatic impaired group and +/- 10 years of the average pooled hepatic impairment group.
--Exclusion criteria for all participants:
Any condition or surgery possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection)
Positive HIV antibodies
Positive drug or alcohol test eGFR <60 mL/min/1.73m2 at screening
Exclusion criteria for non-healthy participants who have hepatic impairment:
Stable concomitant meds and hepatic impairment with no change in the last 28 days
Hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy (defined as <1 year).
A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, PE, liver biopsy, hepatic ultrasound, CT scan, or MRI.
History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 4 weeks prior to screening.
--Severe ascites and/or pleural effusion, except for those categorized as severe hepatic impairment who may be enrolled provided participant is medically stable, per the investigators' medical judgment.
Previously received a kidney, liver, or heart transplant. ALT/AST greater than 5X upper limit normal
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Orange County Research Center | Tustin | California | 92780 | United States | ||
| Orlando Clinical Research Center |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
Participants with varying degrees of hepatic function were enrolled in 4 groups
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | No Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| FG001 | Mild Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 23, 2023 | Jan 24, 2025 |
Not provided
An open-label, single dose, parallel group, multicenter study to investigate the effect of varying degrees of hepatic function on the plasma PK of PF-07923568 after a single, oral 200 mg dose administered in the fed state (standard breakfast).
Not provided
Not provided
Not provided
Not provided
|
| Day -1 through follow-up (Day 29-36) |
| Number of Participants With Laboratory Test Abnormalities | Laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute and percent total neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (blood urea nitrogen/urea and creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin and total protein), urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy, urinary albumin to creatinine ratio and urinary protein to creatinine ratio) and other tests. Abnormality was determined by the investigator. Only lab abnormalities with at least 1 occurrence in participants are reported. | Day -1 and Day 6 |
| Number of Participants With Vital Signs Meeting Categorical Criteria | Supine blood pressure and pulse rate were measured. Categorical classes for vital signs of potential clinical concerns were defined as followed: systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); diastolic blood pressure (DBP) <50 mmHg; pulse rate <40 beats per minute (bpm); pulse rate >120 bpm, and increase from baseline in SBP ≥30 mmHg; decrease from baseline in SBP ≥30 mmHg; increase from baseline in DBP ≥20 mmHg; decrease from baseline in DBP ≥20 mmHg. The baseline measurement was the predose measurement on Day 1. Changes from baseline was defined as the change between the postdose and baseline measurements. | Day -1, Day 1, Day 2, and Day 6 |
| Number of Participants With Electrocardiograms (ECGs) Meeting Categorical Criteria | Number of participants with ECG findings meeting the following criteria: time between the onset of atrial depolarization and onset of ventricular depolarization (PR interval) ≥300 msec; time from ECG Q-wave to the end of the S wave corresponding to ventricular depolarization (QRS duration) ≥140 msec; correct time from ECG Q-wave to the end of the T wave corresponding to electrical systole for heart rate using Fridericia's formula (QTcF interval): ≥450 to <480 msec; QTcF interval ≥480 to <500 msec; QTcF interval: ≥500 msec; PR interval percent change from baseline (≥25/50%): ≥25% if baseline >200 msec or ≥ 50% if baseline ≤200 msec; QRS duration percent change from baseline ≥50%; QTcF interval change from baseline: >30 to ≤60 msec; QTcF interval change from baseline >60 msec. The baseline measurement was the predose measurement on Day 1. Changes from baseline was defined as the change between the postdose and baseline measurements. | Day -1, Day 1, Day 2, and Day 6 |
| Orlando |
| Florida |
| 32809 |
| United States |
| Genesis Clinical Research, LLC | Tampa | Florida | 33603 | United States |
| FG002 | Moderate Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| FG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| COMPLETED | 28 |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | No Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| BG001 | Mild Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| BG002 | Moderate Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| BG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Plasma Maximum Concentration (Cmax) of Sisunatovir Following Administration of a Single Oral Dose | Cmax was the highest concentration observed directly from data | All participants who received at least 1 dose of sisunatovir and had at least 1 of the pharmacokenetic parameters of interest calculated. | Posted | Geometric Mean | Geometric Coefficient of Variation | Nanograms/milliliter (ng/mL) | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Sisunatovir Following Administration of a Single Oral Dose | AUClast was determined using linear/Log trapezoidal method | All participants who received at least 1 dose of sisunatovir and had at least 1 of the pharmacokenetic parameters of interest calculated. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanograms*hour/milliliter (ng*hr/mL) | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Sisunatovir Following Administration of a Single Oral Dose | AUClast + (Clast*/kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminalphase rate constant. | All participants who received at least 1 dose of sisunatovir and had at least 1 of the pharmacokenetic parameters of interest calculated. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | Hours 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 postdose from Day 1 to Day 6 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-related TEAEs, and Discontinuations From Study Due to TEAEs | Adverse event (AE) was any untoward medical occurrence in the participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Serious AE was any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or was considered to be an important medical event. Any events occurring following start of treatment or increasing in severity were counted as treatment-emergent. AEs included both serious and non-serious AEs. | All participants assigned to study intervention and who took at least 1 dose of study intervention. | Posted | Count of Participants | Participants | Day -1 through follow-up (Day 29-36) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Laboratory Test Abnormalities | Laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute and percent total neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (blood urea nitrogen/urea and creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin and total protein), urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy, urinary albumin to creatinine ratio and urinary protein to creatinine ratio) and other tests. Abnormality was determined by the investigator. Only lab abnormalities with at least 1 occurrence in participants are reported. | All participants assigned to study intervention and who took at least 1 dose of study intervention, and who had at least one observation of the given laboratory test and had a laboratory abnormality meeting specified criteria while on study treatment or during lag time. | Posted | Count of Participants | Participants | Day -1 and Day 6 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Vital Signs Meeting Categorical Criteria | Supine blood pressure and pulse rate were measured. Categorical classes for vital signs of potential clinical concerns were defined as followed: systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); diastolic blood pressure (DBP) <50 mmHg; pulse rate <40 beats per minute (bpm); pulse rate >120 bpm, and increase from baseline in SBP ≥30 mmHg; decrease from baseline in SBP ≥30 mmHg; increase from baseline in DBP ≥20 mmHg; decrease from baseline in DBP ≥20 mmHg. The baseline measurement was the predose measurement on Day 1. Changes from baseline was defined as the change between the postdose and baseline measurements. | All participants assigned to study intervention and who took at least 1 dose of study intervention. | Posted | Count of Participants | Participants | Day -1, Day 1, Day 2, and Day 6 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Electrocardiograms (ECGs) Meeting Categorical Criteria | Number of participants with ECG findings meeting the following criteria: time between the onset of atrial depolarization and onset of ventricular depolarization (PR interval) ≥300 msec; time from ECG Q-wave to the end of the S wave corresponding to ventricular depolarization (QRS duration) ≥140 msec; correct time from ECG Q-wave to the end of the T wave corresponding to electrical systole for heart rate using Fridericia's formula (QTcF interval): ≥450 to <480 msec; QTcF interval ≥480 to <500 msec; QTcF interval: ≥500 msec; PR interval percent change from baseline (≥25/50%): ≥25% if baseline >200 msec or ≥ 50% if baseline ≤200 msec; QRS duration percent change from baseline ≥50%; QTcF interval change from baseline: >30 to ≤60 msec; QTcF interval change from baseline >60 msec. The baseline measurement was the predose measurement on Day 1. Changes from baseline was defined as the change between the postdose and baseline measurements. | All participants assigned to study intervention and who took at least 1 dose of study intervention. | Posted | Count of Participants | Participants | Day -1, Day 1, Day 2, and Day 6 |
|
Day -1 through follow-up (Day 29-36)
The time period for actively eliciting and collecting AEs and SAEs ("active collection period") for each participant beginned from the time the participant provides informed consent, which was obtained before before undergoing any study-related procedure and/or receiving study intervention, through and including a minimum of 28 calendar days, after the last administration of the investigational product.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | No Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. | 0 | 8 | 0 | 8 | 1 | 8 |
| EG001 | Mild Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. | 0 | 8 | 0 | 8 | 0 | 8 |
| EG002 | Moderate Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. | 0 | 8 | 0 | 8 | 1 | 8 |
| EG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. | 0 | 4 | 0 | 4 | 1 | 4 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA v26.1 | Non-systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA v26.1 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA v26.1 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA v26.1 | Non-systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 19, 2023 | Jan 24, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000717948 | sisunatovir |
Not provided
Not provided
Not provided
| 45-64 years |
|
| ≥65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Geometric mean ratio |
| 90.89 |
| 2-Sided |
| 90 |
| 54.91 |
| 150.45 |
Moderate Hepatic Impairment versus No Hepatic Impairment |
| Other |
| Geometric mean ratio | 157.23 | 2-Sided | 90 | 84.81 | 291.49 | Severe Hepatic Impairment versus No Hepatic Impairment | Other |
Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
|
| OG003 |
| Severe Hepatic Impairment |
Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
|
| Moderate Hepatic Impairment |
Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| OG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| OG002 | Moderate Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| OG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal.
| OG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
| OG002 | Moderate Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
| OG003 | Severe Hepatic Impairment | Participants received an oral single dose of sisunatovir 200 mg (4 × 50 mg capsules) with the morning meal. |
|
|
|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
|
| Title | Measurements |
|---|---|
|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|